5GH Stock Chart & Stats
€146.52
-€5.40(-4.09%)
At close: 4:00 PM EDT
€146.52
-€5.40(-4.09%)
Day’s Range― - ―
52-Week Range€46.46 - €149.34
Previous CloseN/A
Volume0.00
Average Volume (3M)18.00
Market Cap
€19.52B
Enterprise Value€20.58K
Total Cash (Recent Filing)€1.05B
Total Debt (Recent Filing)€1.70B
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Oct 29, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding134,196,170
10 Day Avg. Volume8
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€164.23Price Target Upside12.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-2.75
Revenue Forecast (FY)€1.17B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And GuidanceRapid revenue growth and a higher full-year outlook indicate broadening adoption across Oncology, Screening, and Biopharma. Sustained volume expansion can strengthen operating leverage and improve Guardant’s position in the expanding precision-oncology market.
Screening Adoption And Market AccessGuideline inclusion and major-payer coverage are structural adoption catalysts that can expand physician referrals and patient access. Rising Shield volumes also support scale efficiencies, potentially improving the economics of Guardant’s early-detection business over time.
Proprietary Data And Diagnostic FranchiseA large, diverse clinical dataset can improve assay development, support biopharma partnerships, and create differentiated real-world evidence capabilities. Combined with 28 company-wide CDx approvals, it reinforces a defensible precision-oncology platform.
Bears Say
High Leverage And Negative EquityHigh debt alongside negative equity materially limits financial flexibility and increases dependence on successful execution or external financing. This balance-sheet strain could constrain investment choices and amplify downside if growth or reimbursement milestones are delayed.
Persistent Losses And Cash BurnGuardant remains reliant on cash reserves while funding operations, capacity expansion, and commercial growth. Although losses and burn are improving, the absence of self-funding cash generation leaves profitability dependent on continued growth and successful cost reduction.
Reimbursement And Operating-Cost UncertaintyDelayed reimbursement decisions and uncertain pricing can slow ASP expansion and make test economics less predictable. At the same time, elevated commercial and infrastructure spending may keep margins and cash flow under pressure before screening reaches sufficient scale.
Guardant Health News
5GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was €46.46 and its highest was €149.34 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is €19.52B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Oct 29, 2026 which is in 60 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Jul 30, 2026. The company reported -€0.772 earnings per share for the quarter, missing the consensus estimate of -€0.653 by -€0.118.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.65.
How many shares outstanding does Guardant Health have?
Guardant Health has 134,196,170 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -€0.772 in its last earnings report, missing expectations of -€0.653. Following the earnings report the stock price went up 7.531%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in DE:5GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€164.23 (12.09% Upside)
€164.23 (12.09% Upside)
Blogger Sentiment
Bullish
DE:5GH Sentiment 81%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $83.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
223.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.57%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
5GH Company Deck
5GH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: broad-based, high-double-digit revenue and volume growth, major FDA approvals (Guardant360 Liquid CDx and a higher-throughput Shield workflow), guideline inclusion and a major payer (UnitedHealth) coverage decision for Shield, record Biopharma results, meaningful margin and cost-per-test improvement initiatives, and expanded commercial reach. Offsetting these positives are elevated operating expenses and investments (S&M and CapEx) to scale Screening, a modest adjusted EBITDA loss and increased free cash flow burn, and outstanding reimbursement/pricing uncertainties (ADLT timing, MolDX/Reveal coverage, USPSTF). On balance, the positive commercial, regulatory and margin trends materially outweigh the near-term cost and reimbursement risks, though execution and payer outcomes remain key near-term sensitivities.View all DE:5GH earnings summaries5GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
5GH Stock 12 Month Forecast
Average Price Target
€164.23
▲(12.09% Upside)